Cybin (TSE:CYBN) has released an update.
Cybin Inc., a clinical-stage neuropsychiatry company, has announced significant advancements in their leading drug candidates, CYB003 for Major Depressive Disorder and CYB004 for Generalized Anxiety Disorder, with a Phase 3 study on the horizon and new patents secured. The company has strengthened its R&D team and maintains a robust cash position of C$183 million, signaling a steady march towards the commercialization of their novel treatments.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
